65,437 trials
Rotavirus Infections
Primary: Intussusception Within 42 Days Following Any Dose of RotaTeq™/Placebo — 6; 5 Participants — p=0.006
ADHD
Primary: Proton Magnetic Resonance Spectroscopy (H MRS) Scan Results - Glutamate(Glu)/Myo-inositol-containing Compounds (Ino) — 1.50; 1.56 MRS Ratio
Type 2 Diabetes Mellitus
Primary: Hospital Length of Stay — 2.7; 3.1 days — p=0.58
Asthma
Primary: Number of Asthma-related Hospitalizations, Asthma-related Emergency Department (ED) Visits, and Combined Hospitalizations/ED Visits Represented Per 100 Person Years…
Systemic Lupus Erythematosus
Primary: SLE Responder Index (SRI) Response Rate at Week 52 — 43.6; 51.4; 57.6 Percentage of participants — p=0.0006
Hypertension
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 1; 0 Participants
Trauma
Primary: Mortality — 0 participants
Leukemia · Myelofibrosis
Primary: Number of Participants With Objective Response — 0; 0; 6 Participants
Iliac Artery Occlusive Disease
Primary: Rate of Major Adverse Clinical Events (MACE) — 0.153 MACE events per 9 months
Leukemia · Chronic Myelogenous Leukemia · Chronic Myeloid Leukemia
Primary: Number of Participants With Complete Response — 3 Participants
Macular Degeneration
Primary: Summary of Adverse Events — 57; 16; 47; 4 participants
Migraine Headache
Primary: Pain Relief at 2 Hours After the Initial Dose of Test Drug — 285; 322; 106; 172 Participants
Hypertension
Primary: Change From Baseline to Week 38 in the Carotid-femoral Pulse Wave Velocity (PWV) — -1.9; -1.7 m/s
Acute Ischemic Stroke
Primary: Number of Participants With Symptomatic Intracerebral Hemorrhage — 0 participants
Hypertension
Primary: Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP) — -7.99; -13.98 mm Hg — p=<0.001